To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.We designed a single-arm prospective, multicentre, open-label phase II study to evaluate the combination of erlotinib (100 mg/d, orally) and weekly FDR-Gem (1000 mg/m(2), infused at 10 mg/m(2) per minute) in a population of previously untreated patients with locally advanced, inoperable, or metastatic pancreatic cancer. Primary endpoint was the rate of progression-free survival at 6 mo (PFS-6); secondary endpoints were overall response rate (ORR), response duration, tolerability, overall survival (OS), and clinical benefit. Treatment was not considered to be of further interest if the PFS-6 was < 20\% (p0 = 20\%), while a PFS-6 > 40\% would be of considerable interest (p1 = 40\%); with a 5\% rejection error (α = 5\%) and a power of 80\%, 35 fully evaluable patients with metastatic disease were required to be enrolled in order to complete the study. Analysis of prognostic factors for survival was also carried out.From May 2007 to September 2009, 46 patients were enrolled (male/female: 25/21; median age: 64 years; median baseline carbohydrate antigen 19-9 (CA 19-9): 897 U/mL; locally advanced/metastatic disease: 5/41). PFS-6 and median PFS were 30.4\% and 14 wk (95\%CI: 10-19), respectively; 1-year and median OS were 20.2\% and 26 wk (95\%CI: 8-43). Five patients achieved an objective response (ORR: 10.9\%, 95\%CI: 1.9-19.9); disease control rate was 56.5\% (95\%CI: 42.2-70.8); clinical benefit rate was 43.5\% (95\%CI: 29.1-57.8). CA 19-9 serum levels were decreased by > 25\% as compared to baseline in 14/23 evaluable patients (63.6\%). Treatment was well-tolerated, with skin rash being the most powerful predictor of both longer PFS (P < 0.0001) and OS (P = 0.01) at multivariate analysis (median OS for patients with or without rash: 42 wk vs 15 wk, respectively, Log-rank P = 0.03). Additional predictors of better outcome were: CA 19-9 reduction, female sex (for PFS), and good performance status (for OS).Primary study endpoint was not met. However, skin rash strongly predicted erlotinib efficacy, suggesting that a pharmacodynamic-based strategy for patient selection deserves further investigation.
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Bria, Emilio;M. Milella
2013-01-01
Abstract
To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.We designed a single-arm prospective, multicentre, open-label phase II study to evaluate the combination of erlotinib (100 mg/d, orally) and weekly FDR-Gem (1000 mg/m(2), infused at 10 mg/m(2) per minute) in a population of previously untreated patients with locally advanced, inoperable, or metastatic pancreatic cancer. Primary endpoint was the rate of progression-free survival at 6 mo (PFS-6); secondary endpoints were overall response rate (ORR), response duration, tolerability, overall survival (OS), and clinical benefit. Treatment was not considered to be of further interest if the PFS-6 was < 20\% (p0 = 20\%), while a PFS-6 > 40\% would be of considerable interest (p1 = 40\%); with a 5\% rejection error (α = 5\%) and a power of 80\%, 35 fully evaluable patients with metastatic disease were required to be enrolled in order to complete the study. Analysis of prognostic factors for survival was also carried out.From May 2007 to September 2009, 46 patients were enrolled (male/female: 25/21; median age: 64 years; median baseline carbohydrate antigen 19-9 (CA 19-9): 897 U/mL; locally advanced/metastatic disease: 5/41). PFS-6 and median PFS were 30.4\% and 14 wk (95\%CI: 10-19), respectively; 1-year and median OS were 20.2\% and 26 wk (95\%CI: 8-43). Five patients achieved an objective response (ORR: 10.9\%, 95\%CI: 1.9-19.9); disease control rate was 56.5\% (95\%CI: 42.2-70.8); clinical benefit rate was 43.5\% (95\%CI: 29.1-57.8). CA 19-9 serum levels were decreased by > 25\% as compared to baseline in 14/23 evaluable patients (63.6\%). Treatment was well-tolerated, with skin rash being the most powerful predictor of both longer PFS (P < 0.0001) and OS (P = 0.01) at multivariate analysis (median OS for patients with or without rash: 42 wk vs 15 wk, respectively, Log-rank P = 0.03). Additional predictors of better outcome were: CA 19-9 reduction, female sex (for PFS), and good performance status (for OS).Primary study endpoint was not met. However, skin rash strongly predicted erlotinib efficacy, suggesting that a pharmacodynamic-based strategy for patient selection deserves further investigation.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
